- Home
- SBFM vs LIXT Comparison
SBFM vs LIXT Comparison
Compare SBFM & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBFM
- LIXT
- Stock Information
- Founded
- SBFM 2006
- LIXT 2005
- Country
- SBFM United States
- LIXT United States
- Employees
- SBFM N/A
- LIXT N/A
- Industry
- SBFM Biotechnology: Pharmaceutical Preparations
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- SBFM Health Care
- LIXT Health Care
- Exchange
- SBFM Nasdaq
- LIXT Nasdaq
- Market Cap
- SBFM 4.6M
- LIXT 4.1M
- IPO Year
- SBFM N/A
- LIXT N/A
- Fundamental
- Price
- SBFM $1.51
- LIXT $1.33
- Analyst Decision
- SBFM Strong Buy
- LIXT
- Analyst Count
- SBFM 1
- LIXT 0
- Target Price
- SBFM $15.00
- LIXT N/A
- AVG Volume (30 Days)
- SBFM 104.9K
- LIXT 22.1K
- Earning Date
- SBFM 05-15-2025
- LIXT 05-12-2025
- Dividend Yield
- SBFM N/A
- LIXT N/A
- EPS Growth
- SBFM N/A
- LIXT N/A
- EPS
- SBFM N/A
- LIXT N/A
- Revenue
- SBFM $36,234,578.00
- LIXT N/A
- Revenue This Year
- SBFM $192.48
- LIXT N/A
- Revenue Next Year
- SBFM N/A
- LIXT N/A
- P/E Ratio
- SBFM N/A
- LIXT N/A
- Revenue Growth
- SBFM 35.51
- LIXT N/A
- 52 Week Low
- SBFM $1.17
- LIXT $1.02
- 52 Week High
- SBFM $11.39
- LIXT $3.50
- Technical
- Relative Strength Index (RSI)
- SBFM 54.20
- LIXT 50.90
- Support Level
- SBFM $1.37
- LIXT $1.16
- Resistance Level
- SBFM $1.56
- LIXT $1.49
- Average True Range (ATR)
- SBFM 0.08
- LIXT 0.11
- MACD
- SBFM 0.02
- LIXT 0.00
- Stochastic Oscillator
- SBFM 73.68
- LIXT 51.45
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.